ライフサイエンスコーパス: buparlisib

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 rved for the structurally related 4 (BKM120, buparlisib).

2 y assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or placebo, plus intraven

3 chnology (block size of six) to receive oral buparlisib (100 mg per day) or matching placebo starting

4 e of 6) on day 15 of cycle 1 to receive oral buparlisib (100 mg/day) or matching placebo, starting on

5 Buparlisib, a pan-PI3K inhibitor, has shown preclinical

6 nuous or intermittent (five on/two off days) buparlisib administration on an every-4-week schedule.

7 Buparlisib, an oral reversible inhibitor of all class I

8 Phase III trials of buparlisib and endocrine therapy in patients with ER-pos

9 The letrozole and buparlisib combination was safe, with reversible toxicit

10 s occurred in 15 (20%) of 76 patients in the buparlisib group and 17 (22%) of 78 patients in the plac

11 vival was 4.6 months (95% CI 3.5-5.3) in the buparlisib group and 3.5 months (2.2-3.7) in the placebo

12 reported for 43 (57%) of 76 patients in the buparlisib group and 37 (47%) of 78 in the placebo group

13 e reported in 62 (82%) of 76 patients in the buparlisib group and 56 (72%) of 78 patients in the plac

14 occurred in ten (3%) of 288 patients in the buparlisib group and in six (4%) of 140 in the placebo g

15 atment-related (cardiac failure [n=1] in the buparlisib group and unknown reason [n=1] in the placebo

16 reported in 134 (23%) of 573 patients in the buparlisib group compared with 90 [16%] of 570 patients

17 reported in 64 (22%) of 288 patients in the buparlisib group versus 23 (16%) of 140 in the placebo g

18 vival was 6.8 months (95% CI 4.9-7.1) in the buparlisib group versus 4.0 months (3.1-5.2) in the plac

19 vival was 6.9 months (95% CI 6.8-7.8) in the buparlisib group versus 5.0 months (4.0-5.2) in the plac

20 most common grade 3-4 adverse events in the buparlisib group versus the placebo group were increased

21 vival was 6.8 months (95% CI 5.0-7.0) in the buparlisib group vs 4.5 months (3.3-5.0) in the placebo

22 ents (occurring in >/=10% of patients in the buparlisib group vs the placebo group) were hyperglycaem

23 f this randomised phase 2 study suggest that buparlisib in combination with paclitaxel could be an ef

24 BKM120 (Buparlisib) is one of the most advanced phosphoinositide

25 , 432 patients were randomly assigned to the buparlisib (n=289) or placebo (n=143) groups.

26 countries were randomly assigned to receive buparlisib (n=576) or placebo plus fulvestrant (n=571).

27 INTERPRETATION: The safety profile of buparlisib plus fulvestrant does not support its further

28 essed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced br

29 We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced br

30 This phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and pr

31 lled and randomly assigned to receive either buparlisib plus paclitaxel (n=79) or placebo plus paclit

32 Buparlisib's maximum-tolerated dose (MTD) was 100 mg/d.

33 Nonetheless, the efficacy of buparlisib supports the rationale for the use of PI3K in

34 We assessed whether the addition of buparlisib to paclitaxel improves clinical outcomes comp

35 and pertuzumab but respond to PI3K inhibitor buparlisib (TPB).

36 ree survival was significantly longer in the buparlisib versus placebo group (3.9 months [95% CI 2.8-

37 ost frequent grade 3-4 adverse events in the buparlisib versus placebo group were elevated alanine am

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。